VolitionRx (VNRX) said Wednesday it has entered into a collaboration with Japanese in-vitro diagnostics specialist Sysmex to optimize its Nu.Q NETs H3.1 assay on the Sysmex platform.
Financial terms of the collaboration were not provided.
The two companies have started the optimization phase of the test in diseases associated with NETosis, which is implicated in diseases such as sepsis, VolitionRx said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments